CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients

By P. Ott, F. Hodi, C. Robert. Clinical Cancer Research, 2013

646 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome (2017, background): “Efforts to use monoclonal antibodies (mAbs) to target and block these immunoinhibitory interactions have led to a new era of immunotherapy based agents for cancer therapy (Freeman et al., 2000; Topalian et al., 2012; Ott et al., 2013).”
OMIP‐050: A 28‐color/30‐parameter Fluorescence Flow Cytometry Panel to Enumerate and Characterize Cells Expressing a Wide Array of Immune Checkpoint Molecules (2018, background): “Immunotherapy has shown clinical benefit in certain solid tumors, although the markers predicting a successful response remain poorly defined (1).”
CTLA-4 and PD-1 Pathways (2016, background): “This has the potential to provide a more targeted signal with less unwanted toxicity, as selftolerance mediated through PD-1:PD-L2 interactions should be preserved.(37,49) Furthermore, as PD-L1 is known to bind CD80 as well as PD-1 to deliver inhibitory signals to T cells,(33) PDL1 inhibition with a”